The mission of new startup Colossal, which has raised $15 million to date, is to genetically reengineer a cold-resistant elephant with all the core biological traits of the extinct woolly mammoth.

Rare Disease

Switzerland-based Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.

Investment firm Blackstone Life Sciences and Alnylam Pharmaceuticals announced a broad strategic collaboration worth up to $2 billion.

Takeda Pharmaceutical started 2019 with a spate of cell therapy collaborations designed to advance the company’s novel immuno-oncology portfolio. The three collaborations will accelerate the discovery of next-generation cancer immunotherapies.

There is a new player in the southern California biotech industry as new venture firm Westlake Village BioPartners launched with a $320 million fund.

German-based life sciences giant Bayer AG is digging a deep foundation in the booming biotech hub of Boston.

Startup biotech companies have a new place to call home in downtown Manhattan thanks to Alexandria Real Estate Equities.

April 19, 2016By Mark Terry, Breaking News Staff   DalCor Pharmaceuticals, which maintains offices in San Mateo, Calif., Switzerland, the UK and Montreal, Canada, announced today that it had wrapped up a private financing round valued at $150 million. Late in 2015, the company closed on a $50 million Series A round, and completed […]

February 19, 2016By Mark Terry, Breaking News Staff   Cambridge, Mass.-based venture capital firm Atlas Venture launched another Cambridge biotech startup yesterday, AvroBio. No financial details were disclosed. The company is founded on two novel cell and gene therapies that came out of the laboratories of Christopher Paige and Jeffrey Medin at the University […]